Product information and disease descriptionPlace of product in therapyApproaches to treatment
Heterogeneity of treatment effect
11 evidence topics · 12 sources
Summary
- Dose: the sponsor reports a difference between doses at 48 months in two statements. The third quarter 2026 release states that high-dose patients showed 1.1 points less decline on cUHDRS and 0.33 points less decline on TFC than low-dose patients. The four-year data release reports mean changes from baseline of –0.91 (high dose) and −1.94 (low dose) on cUHDRS, a difference of 1.03, and −0.30 and −0.70 on TFC, a difference of 0.40.
- Striatal volume: in natural history data presented with the AMT-130 analyses, baseline striatal volume predicted clinical progression in TRACK-HD and predicted cUHDRS decline in the absence of other covariates, and was no longer predictive of cUHDRS or TFC decline when propensity score adjustments were applied. A fourth cohort of six participants with lower striatal volumes than participants in previous cohorts received high-dose AMT-130, with dosing completed in the fourth quarter of 2025.
- Planned analyses: ICER's research protocol plans, data permitting, to evaluate treatment effect modification by HD stage (HD-ISS stages 2 and 3), concomitant antidopaminergic medication, and striatal volume. ICER's model analysis plan states that no heterogeneity and subgroup analyses are planned because currently available trial data are insufficient to support them. A public comment from Prilenia identified concomitant antidopaminergic medications as a pharmacologically important covariate that a chance imbalance in small studies can shift.
- Natural history: in a progression model, TFC progression in individuals with HD-ISS 2 is not expected to differ from that in HD-ISS 3, and progression rates correlate weakly between clinical scores. In 960 participants, longer disease duration and better cognitive status at baseline were associated with less rapid TFC decline.
- Other HD therapies: exploratory GENERATION HD1 analyses suggested benefit in younger participants with lower disease burden, but in GENERATION HD2 the biomarker effects did not translate into a meaningful clinical improvement. For pridopidine, post hoc analyses suggested benefit in participants not receiving antidopaminergic medications, and the European Medicines Agency noted that the validity and relevance of the subgroup results had not been demonstrated.
Dose response: high dose compared with low dose at 48 months
Baseline striatal volume as a predictor of progression in natural history data
Planned evaluation of treatment effect modification by subpopulation
Heterogeneity and subgroup analyses not planned
Antidopaminergic medication as an effect modifier: public comment by Prilenia
Progression by subpopulation and endpoint: disease progression model
“For instance, PIN and CAP can effectively enrich the population with patients more likely to progress, particularly when using TFC (Figure 5, A and B).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Moreover, when using TFC as an end point, the progression rate in individuals with HD-ISS = 2 is not expected to be different from the rate in those with HD-ISS = 3, in contrast to other clinical measurements such as SMDT (Figure 5C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, the weak correlation in progression rates between different clinical scores indicates that patients likely to progress based on one score may not necessarily progress based on other scores.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline covariates of functional decline: cohort of 960 participants
“In multivariate analysis (n = 960), longer disease duration and better cognitive status at baseline were associated with a less rapid rate of decline in TFC score, whereas depressive symptomatology was the only factor associated with more rapid decline on the IS score.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Tominersen: exploratory subgroup finding tested in GENERATION HD2
“GENERATION HD2 was initiated following exploratory analyses of the phase III GENERATION HD1 study, which suggested that younger participants with lower disease burden might derive benefit from lower-dose, less frequent administration of tominersen.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After completion of the planned 16-month treatment period in all 301 participants, top-line analyses showed that tominersen was well tolerated and achieved significant reductions in mHTT protein and NfL concentrations compared with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, these biomarker effects did not translate into a meaningful improvement in clinical outcomes, and Roche therefore discontinued further clinical development of tominersen.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pridopidine: post hoc subgroup without antidopaminergic medication
“PRECISE-HD seeks to build on findings from numerous large trials of pridopidine in HD that failed to demonstrate efficacy, most recently the phase III PROOF-HD study (NCT04556656),” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although the primary and key secondary endpoints (change in TFC and cUHDRS at week 65) were not met in the overall study population, post-hoc and sensitivity analyses suggested potential benefit among participants who were not receiving antidopaminergic medications.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote